{"transactions":[{"id":1104555,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":78259,"kind":"person","name":"Blunt Roshawn A.","position":1,"cik":"0001787773","reported_name":"Blunt Roshawn A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T16:15:22.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.57 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").[continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":0.95,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001415889-25-017828","document":"form4-06202025_040614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000141588925017828/form4-06202025_040614.xml","form_type":"4"}},{"id":1104554,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":78259,"kind":"person","name":"Blunt Roshawn A.","position":1,"cik":"0001787773","reported_name":"Blunt Roshawn A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T16:15:22.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.57 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").[continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.48,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001415889-25-017828","document":"form4-06202025_040614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000141588925017828/form4-06202025_040614.xml","form_type":"4"}},{"id":1104553,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":78259,"kind":"person","name":"Blunt Roshawn A.","position":1,"cik":"0001787773","reported_name":"Blunt Roshawn A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T16:15:22.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.57 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").[continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":3.53,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001415889-25-017828","document":"form4-06202025_040614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000141588925017828/form4-06202025_040614.xml","form_type":"4"}},{"id":1104552,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":78259,"kind":"person","name":"Blunt Roshawn A.","position":1,"cik":"0001787773","reported_name":"Blunt Roshawn A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T16:15:22.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":41200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.57 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").[continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":17.1,"expiration_date":"2031-11-10","underlying":"Common Stock","underlying_shares":41200},"source":{"system":"sec-edgar","filing":"0001415889-25-017828","document":"form4-06202025_040614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000141588925017828/form4-06202025_040614.xml","form_type":"4"}},{"id":1468563,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":78259,"kind":"person","name":"Blunt Roshawn A.","position":1,"cik":"0001787773","reported_name":"Blunt Roshawn A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-26T16:33:40.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":34000,"derivative":{"exercise_price":0.95,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001415889-24-018233","document":"form4-06262024_080637.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000141588924018233/form4-06262024_080637.xml","form_type":"4"}},{"id":1843995,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":78259,"kind":"person","name":"Blunt Roshawn A.","position":1,"cik":"0001787773","reported_name":"Blunt Roshawn A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:12:22.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":34000,"derivative":{"exercise_price":1.48,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001209191-23-039690","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919123039690/doc4.xml","form_type":"4"}},{"id":1861745,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":78259,"kind":"person","name":"Blunt Roshawn A.","position":1,"cik":"0001787773","reported_name":"Blunt Roshawn A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T22:17:42.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":14815,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":14815,"derivative":{"exercise_price":9.01,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":14815},"source":{"system":"sec-edgar","filing":"0001209191-23-035566","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000120919123035566/doc4.xml","form_type":"4"}},{"id":2197162,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":78259,"kind":"person","name":"Blunt Roshawn A.","position":1,"cik":"0001787773","reported_name":"Blunt Roshawn A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-02T23:16:41.000Z","date":"2022-08-02","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option vest and become exercisable in equal monthly installments over a three-year period."}],"balance_after":35000,"derivative":{"exercise_price":2.8,"expiration_date":"2032-08-01","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-22-043994","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000120919122043994/doc4.xml","form_type":"4"}},{"id":2219137,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":78259,"kind":"person","name":"Blunt Roshawn A.","position":1,"cik":"0001787773","reported_name":"Blunt Roshawn A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-29T16:12:43.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":34000,"derivative":{"exercise_price":3.53,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001209191-22-039784","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919122039784/doc4.xml","form_type":"4"}},{"id":2512195,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":78259,"kind":"person","name":"Blunt Roshawn A.","position":1,"cik":"0001787773","reported_name":"Blunt Roshawn A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-11-15T13:45:25.000Z","date":"2021-11-11","kind":"grant","acquired":true,"shares":41200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in three equal annual installments following the date of grant."}],"balance_after":41200,"derivative":{"exercise_price":17.1,"expiration_date":"2031-11-10","underlying":"Common Stock","underlying_shares":41200},"source":{"system":"sec-edgar","filing":"0001209191-21-064413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919121064413/doc4.xml","form_type":"4"}},{"id":3275130,"issuer":{"id":108664,"kind":"organization","name":"DMK PHARMACEUTICALS Corp","symbol":"DMK"},"owners":[{"id":78259,"kind":"person","name":"Blunt Roshawn A.","position":1,"cik":"0001787773","reported_name":"Blunt Roshawn A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Appreciation Right","published_at":"2020-02-13T16:21:25.000Z","date":"2019-08-26","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Stock Appreciation Right is the economic equivalent of one share of ADMP common stock and can only be settled in cash."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Appreciation Right (\"SAR\") will vest with respect to 8,333 shares subject to the SAR on the six-month anniversary of the date of grant, and thereafter 1,388 shares shall vest on each monthly anniversary of the date of grant with all remaining unvested shares subject to the SAR vesting on the thirty-sixth (36th) monthly anniversary of the date of grant."}],"balance_after":50000,"derivative":{"exercise_price":0.97,"expiration_date":"2026-08-26","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001387131-20-001553","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/887247/000138713120001553/ownership.xml","form_type":"4"}}]}